0001104659-24-076946.txt : 20240701 0001104659-24-076946.hdr.sgml : 20240701 20240701180019 ACCESSION NUMBER: 0001104659-24-076946 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240626 FILED AS OF DATE: 20240701 DATE AS OF CHANGE: 20240701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shutterly Andrew CENTRAL INDEX KEY: 0002028603 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 241092160 MAIL ADDRESS: STREET 1: C/O ALTIMMUNE, INC. STREET 2: 910 CLOPPER ROAD, SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 3 1 tm2418528-1_3seq1.xml OWNERSHIP DOCUMENT X0206 3 2024-06-26 0 0001326190 Altimmune, Inc. ALT 0002028603 Shutterly Andrew C/O ALTIMMUNE, INC. 910 CLOPPER ROAD, SUITE 201S GAITHERSBURG MD 20878 0 1 0 0 See Remarks Common Stock, par value $0.0001 10113 D Stock Option (Right to Buy) 7.05 2032-03-17 Common Stock, par value $0.0001 20000 D Stock Option (Right to Buy) 12.88 2033-01-30 Common Stock, par value $0.0001 25000 D Stock Option (Right to Buy) 4.48 2033-05-22 Common Stock, par value $0.0001 15000 D Stock Option (Right to Buy) 9.28 2034-01-25 Common Stock, par value $0.0001 12000 D Restricted Stock Units 0.00 Common Stock, par value $0.0001 11250 D Restricted Stock Units 0.00 Common Stock, par value $0.0001 3000 D Twenty-five percent of the shares underlying the option became vested and exercisable on March 17, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following March 17, 2023, subject to the reporting person's continued service through the applicable vesting date. Twenty-five percent of the shares underlying the option became vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date. Twenty-five percent of the shares underlying the option became vested and exercisable on May 22, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following May 22, 2024, subject to the reporting person's continued service through the applicable vesting date. Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date. The RSUs will vest in equal annual installments of 3,750 shares on January 30, 2025, January 30, 2026 and January 30, 2027, subject to the reporting person's continued service through the applicable date, and have no expiration date. The RSUs become vested and exercisable over four 4 years with 25% of the shares vesting on January 25, 2025, with the remainder vesting in equal annual installments for the following three years, subject to the reporting person's continued service through the applicable date, and have no expiration date. Acting Chief Financial Officer. Exhibit 24 - Power of Attorney. /s/ Vipin K. Garg, as Attorney-in-Fact 2024-07-01 EX-24 2 tm2418528d1_ex24.htm EXHIBIT 24

Exhibit 24

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Vipin K. Garg and Siavosh Salimi, signing singly, the undersigned’s true and lawful attorney-in-fact to:

(1)

execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Altimmune, Inc. (the “Company”), (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the United States Securities and Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5, (iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each thereof, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

(2)

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D. Schedule 13G or any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3)

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney may be filed with the United States Securities and Exchange Commission as a confirming statement of the authority granted herein. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned’s capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 26^th day of June 2024.

/s/ Andrew Shutterly
Signature

Andrew Shutterly
Print Name